Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03609671 · ClinicalTrials.gov registry record · NA

Emotions Immunology and Breast Cancer

A NA study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Luz A. Venta, MD.

Completed
Registry status
NA
Development phase
17
Enrollment target
2
Study locations

NCT03609671: Completed NA study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Luz A. Venta, MD.

NCT03609671 is a NA study of Breast Cancer and Triple Negative Breast Cancer that has completed, run by Luz A. Venta, MD. The registered enrollment target is 17 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03609671, a NA study of Breast Cancer and Triple Negative Breast Cancer, has completed, sponsored by Luz A. Venta, MD.

COMPLETED
Registry status
NA
Development phase
17 participants
Enrollment target
2
Study locations

Study Summary

Pilot study representing a proof of concept regarding the potential for immune system enhancement with psychotherapy, resulting in improved immunological response at lumpectomy or mastectomy in patients undergoing neoadjuvant chemotherapy.

Primary Outcome

The self-reported Adverse Childhood Experience Questionnaire measures different types of abuse, neglect, and other hallmarks of a challenging childhood. Scores range from 0-10, with 10 indicating highest childhood abuse \&/or neglect exposure with greater risk for negative consequences later in life, and 0 is lowest exposure and lower risk for negative consequences.questionnaires with immune responses. Pathologic tumor response is our measurable endpoint, focusing on immune cells in the tumor be

Interventions

  • BEHAVIORAL Standard of Care + Experimental Individualized Therapy
  • OTHER Control: Standard of Care

Study Locations (2)

Texas

  • Houston Methodist Hospital Cancer Center - Houston
  • Houston Methodist Hospital - Houston

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2015-11-23
Est. Completion 2019-03-18
Phase NA
Luz A. Venta, MD

1 total trials

What the finished NCT03609671 record still lists

NCT03609671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care + Experimental Individualized Therapy is the first listed.

NCT03609671 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03609671 about?

NCT03609671 is a clinical study titled "Emotions Immunology and Breast Cancer". Pilot study representing a proof of concept regarding the potential for immune system enhancement with psychotherapy, resulting in improved immunological response at lumpectomy or mastectomy in patients undergoing neoadjuvant chemotherapy.

What is the current status of trial NCT03609671?

This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2015-11-23. Estimated completion is 2019-03-18.

What conditions does trial NCT03609671 study?

This clinical trial studies the following conditions: Breast Cancer, Triple Negative Breast Cancer, Emotions, Immunology.

What interventions are being tested in trial NCT03609671?

The interventions under investigation include: Standard of Care + Experimental Individualized Therapy (BEHAVIORAL), Control: Standard of Care (OTHER).

Who is sponsoring clinical trial NCT03609671?

This trial is sponsored by Luz A. Venta, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03609671 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03609671's enrollment target sits among peer trials

17 1129th of 1224 higher than 91 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03609671, the US trial registry maintained by the National Library of Medicine. NCT03609671 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.